BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $138
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman has maintained a Market Perform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raised the price target from $129 to $138.
May 02, 2024 | 2:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital maintains a Market Perform rating on Neurocrine Biosciences and raises the price target from $129 to $138.
The increase in price target by BMO Capital suggests a positive outlook on the stock's future performance, potentially leading to increased investor confidence and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100